**[262] XACT ROBOTICS TRANSFORMATIONAL ROBOTIC STEERING SYSTEM**

**Chen Levin1, 1 Xact Robotics Ltd**

* **Investment Rational**

XACT Robotics (“XACT”) develops a transformational platform robotic steering system, utilizing any imaging modality in any clinical setting, enabling more physicians to successfully treat more patients. XACT’s first product is intended for use in CT-guided interventional procedures. The product overcomes common challenges with CT-guided procedures, allowing for safe, accurate, predictable and consistent positioning of needles, ports, or other tools, while drastically reducing the required learning curve.

* **Business Strategy**

XACT is positioned to address the growing market needs for accurate tool insertion under image-guidance in minimally invasive procedures. The system is versatile; it can be used with any imaging modality and manufacturer, it is comprised of both capital equipment and disposable parts presenting low expense in comparison with existing robotic systems, it is small and portable, and the Company has a diverse patent portfolio and pipeline.

* **Core Technology**

XACT provides technological features no other system provides:

1. Tool insertion and steering: XACT’s core algorithm calculates the manipulations required to perform the needle/tool insertion and steering to the selected target according to the planned trajectory.
2. Closed-loop control: XACT allows for ongoing real-time corrections to the needle trajectory and compensation for target movement in order to keep the needle/tool on the planned trajectory.
* **Product Profile/Pipeline**

Future development will allow adapting XACT’s platform for use with any imaging system. XACT’s first product is a robotic steering and insertion system for use in CT-guided interventional procedures in the abdomen (such as ablations, biopsies, etc.), requiring accurate needle/tool placement. This in itself, represents a very large market opportunity considering the amount of procedures being performed on a routine basis.

The National Institute of Health (“NIH”) Center for Interventional Oncology is collaborating with XACT tin its development efforts.

* **What's Next?**

The company is currently performing in-vivo studies and further development of its first generation product intended to begin clinical trials in Q1 2017, leading to CE submission during Q2 2017 and FDA submission during Q4 2017.